Merck Stock Drops 9.5% After Scrapping Blood Cancer Drug, but Analysts See Buying Opportunity at 16x Forward Earnings

Bearish (-0.3)Impact: Medium

Published on · By VibeTrader

Get AI analysis of the markets behind this story

Build and test trading strategies with AI. 3-day free trial · Cancel anytime

Try VibeTrader free

Merck (MRK) stock fell 9.5% in the week ended November 20, 2026, slightly underperforming the S&P 500's 8.6% decline, after the company discontinued development of nemtabrutinib, an experimental blood cancer drug acquired through its $2.7 billion ArQule deal [1]. An independent review of a Phase 3 trial determined that the drug's benefits may not outweigh its risks [1]. Despite this setback, the impact on Merck's overall business appears limited, as nemtabrutinib represented a small loss relative to Keytruda's $31.7 billion in 2025 sales [1]. The discontinuation benefits competitor Eli Lilly (LLY), whose rival drug Jaypirca generated $228 million in third-quarter sales, up 59% [1].

Merck also achieved a significant legal victory when a German appeals court overturned a preliminary injunction that Halozyme Therapeutics (HALO) had won in December 2025 against under-the-skin Keytruda [1]. However, a separate Dutch ruling from October restricting the drug in eight European markets remains in effect [1]. The company's third-quarter financial performance showed resilience, with sales rising 5% to $18.1 billion, and Merck raised the low end of its 2026 sales guidance to a range of $66.8-$67.3 billion [1]. Additionally, the company increased its quarterly dividend to $0.88 from $0.85 [1].

Analysts maintain a constructive outlook despite the recent decline. Consensus normalized earnings per share is expected to fall to $2.79 in 2026 due to acquisition charges, but is projected to recover to $8.96 in 2027, returning to 2025 levels [1]. CFO Caroline Litchfield characterized Keytruda's U.S. patent loss in 2028 as "really more of a hill on the overall revenues of our company," a characterization with which analysts agree [1]. At approximately 16x forward earnings following the decline, Merck appears attractively valued compared to its five-year average of 14x [1]. The $162 consensus price target sits approximately 21% above the November 20 close of $133.72 [1], suggesting meaningful upside potential for investors.

CONCLUSION

Merck's 9.5% weekly decline appears overdone given the limited financial impact of the nemtabrutinib discontinuation and the company's strong underlying fundamentals, including a 5% sales increase and raised 2026 guidance. At 16x forward earnings with a $162 consensus price target implying 21% upside, the stock presents a potential buying opportunity for investors concerned about Keytruda's 2028 patent expiration.

Turn today's news into tomorrow's trade.

Build trading strategies without code, test them against historical data, and connect your broker account.

Try VibeTrader free

3-day free trial · Cancel anytime

Feel free to email us at team@vibetrader.com

Was this page helpful?

Related Articles

Applied Aerospace & Defense Stock Plummets 23.5% on Analyst Downgrades, Supply Chain Woes, and Legal Investigations

Applied Aerospace & Defense (AADX) experienced a severe market selloff this week...

Read full article

Bitcoin Drop to $55,000 Triggers $240 Million in DeFi Liquidation Risk Across Aave and Compound

Bitcoin liquidations on decentralized finance platforms occurred on November 21,...

Read full article

US Dollar Surges 2.5% in November as Fed Rate Hike Fears Drive Flight to Safety, Outperforming Bitcoin, Gold, and Stocks

The US dollar has emerged as the clear winner among major asset classes in Novem...

Read full article
Sources: tikr.com